Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
Journal
Alimentary pharmacology & therapeutics
Journal Volume
42
Journal Issue
7
Pages
829
Date Issued
2015-10
Author(s)
Zeuzem, S
Flisiak, R
Vierling, J M
Mazur, W
Mazzella, G
Thongsawat, S
Abdurakhmanov, D
Van Kính, N
Calistru, P
Heo, J
Stanciu, C
Gould, M
Makara, M
Buggisch, P
Samuel, D
Mutimer, D
Nault, B
Merz, M
Bao, W
Griffel, L H
Brass, C
Naoumov, N V
Abstract
Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance.
SDGs
Type
journal article